

April 20, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

Dear Sirs,

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLS

## Sub: Outcome of the Board Meeting - April 20, 2022

The Board of Glenmark Life Sciences Limited at its meeting held on April 20, 2022, has, inter alia, considered and approved:

- The audited Financial Results for the Year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The copy of the said results together with Management Discussion & Analysis, Press Release, Auditors Report and Declaration of unmodified opinion are enclosed herewith. These are also being made available on the website of the Company at <a href="https://www.glenmarklifesciences.com">www.glenmarklifesciences.com</a>.
- Recommended final Dividend of Rs. 10.5 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
- On the recommendations of Nomination and Remuneration Committee and approval of the Audit Committee, Board approved the appointment of Mr. Tushar P. Mistry as the Chief Financial Officer (designated as Key Managerial Personnel) of the Company with effect from June 1, 2022.
- 4. Mr. Bhavesh Pujara has resigned as the Chief Financial Officer of the Company with effect from the close of business hours on April 22, 2022. Consequently, he also ceases to be the Key Managerial Personnel of the Company.

The said meeting of the Board commenced at 4.10 p.m. and concluded at 7.10 p.m.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Life Sciences Limited

**Rudalf Corriea** 

**Company Secretary & Compliance Officer** 

Encl: As above





The relevant details pursuant to Regulation 30 of the Listing Regulations are as follows:

Appointment of Chief Financial Officer of the Company:

Sr. No.	Particulars	Information of Such Event
1.	Reason for change viz. appointment or resignation, removal death or otherwise	Mr. Tushar P. Mistry has been appointed as the Chief Financial Officer (designated as Key Managerial Personnel) of the Company.
2.	Date of Appointment <del>/ cessation (as applicable)</del> & Term of Appointment	With Effect from June 1, 2022
3.	Brief profile (in case of appointment)	Mr. Tushar P. Mistry is a qualified Chartered Accountant, ICWA from Institute of Cost & Works Accountant of India and holds a Bachelor's degree in Commerce from Mumbai University. He will join us from Sequent Scientific Limited, where he is working as Chief Financial Officer. Prior to Sequent Scientific Limited, he was associated with Wockhardt Limited for almost 17 years, where he played various roles and in his last stint worked as Asst. Vice President. In addition to leading the finance operations, he played a key role in acquisition of various companies at Sequent and held various financial leadership roles at Wockhardt Limited.
4.	Disclosure of relationships between Directors (in case of appointment of a Director	N.A.

**Resignation of Chief Financial Officer:** 

Sr. No.	Particulars	Information of Such Event
1	Reason for change viz. appointment or resignation, removal death or otherwise	Mr. Bhavesh Pujara has resigned as the Chief Financial Officer of the Company.
2.	Date of Appointment/cessation (as applicable) & Term of Appointment	Close of business hours on April 22, 2022
3.	Brief profile (in case of appointment)	N.A.
4.	Disclosure of relationships between Directors (in case of appointment of a Director	N.A.

